Working With Patient Advocacy Groups Without Burning the Relationship
Advocacy groups can be a site's most durable recruitment channel — but only if you approach them before you need enrollments. How to build relationships that produce referrals and keep producing them.
By Trialflow Team
Patient advocacy groups are one of the few recruitment channels that get better over time instead of more expensive. A paid ad campaign resets to zero the day you stop funding it. A relationship with a regional disease foundation compounds — the group learns what your site does well, and their members learn that you treat their people decently.
Most sites approach advocacy groups wrong, though. They show up with a study that needs 14 patients by the end of the quarter and ask for a newsletter blast. That rarely works, and it quietly burns the relationship.
Why groups say no (and what they're actually protecting)
Advocacy organizations hold their member list as their single most valuable asset. Their credibility with patients is the whole business. When you ask for a blast, you're asking them to put their name behind your study, your coordinators, and your sponsor's protocol — usually before they know anything about any of the three.
The common objections sites hear:
- "We don't promote individual sites." Many national groups only list trials through registries or sponsor-level partnerships.
- "The protocol looks burdensome." Groups read inclusion criteria more carefully than sponsors expect. Monthly lumbar punctures and a 20-mile radius requirement will get flagged.
- "We've been burned." A site that didn't return calls or dropped referred patients after screen failure leaves a long memory.
Start before you need them
The most productive site relationships with advocacy groups started with the site giving something away. Concretely:
- Offer education, not recruitment. A PI speaking at a chapter meeting about what's in the research pipeline for their condition — no specific study pitch — builds more goodwill than any flyer.
- Attend their events as attendees. Walks, conferences, support group meetings. Be a face people recognize before you're a face asking for something.
- Share your trial portfolio broadly. Give them a standing one-page list of what you have open, updated quarterly, so they can surface options when a member asks.
- Report back. Tell them when a study they supported finished enrolling, and what happened. Groups almost never hear results.
Match the group to the study
National organizations are good for awareness and registry listings but rarely drive local volume. Regional chapters, condition-specific Facebook groups run by patient leaders, and single-disease foundations for rare conditions are where referrals actually come from. For rare disease work, a well-connected parent advocate can outperform every other channel you have combined.
Handle referrals differently
Advocacy referrals arrive pre-educated and highly motivated, which means they also screen-fail at painful rates — they've often tried every therapy and taken every drug on your exclusion list. Two practical adjustments:
- Pre-screen fast and personally. These patients expect a human. A portal autoresponder reads as dismissive.
- Close the loop on every screen failure. Explain why, suggest what else might fit, and offer to flag them for future protocols. The advocate who referred them will hear about this conversation either way.
Keep it documented
Track which group each referral came from so you can tell the advocate something real at the next meeting. "Your October newsletter produced nine inquiries and three randomizations" is the kind of specificity that gets you the next newsletter slot — and gives you something defensible when a sponsor asks how you plan to reach a hard-to-find population.
Enrolling studies shouldn't be this hard
Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.
Request a Demo